2022 World Conference on Lung Cancer (ePosters)-EP02.01-005. The Efficacy of Platinum-Based Chemotherapy as Adjuvant Therapy in EGFR Mutant Lung Adenocarcinoma

EP02.01-005. The Efficacy of Platinum-Based Chemotherapy as Adjuvant Therapy in EGFR Mutant Lung Adenocarcinoma

Pdf Summary

A study was conducted to evaluate the efficacy of platinum-based adjuvant chemotherapy in patients with stage II-IIIA EGFR mutant lung adenocarcinoma. The study included a total of 90 patients who underwent complete resection between January 2008 and December 2018. The patients were evaluated for overall survival (OS) and relapse-free survival (RFS) based on various factors including age, sex, performance status, smoking index, respiratory function, comorbidity index, and pathological stage.<br /><br />The results showed that adjuvant therapy was not a prognostic factor for EGFR mutants in both OS and RFS. There was no significant difference in OS and RFS between the surgery-only group and the adjuvant group. This suggests that platinum-based adjuvant chemotherapy may be less effective in EGFR mutant lung adenocarcinoma.<br /><br />The study also performed multivariable analysis to assess the impact of different factors on RFS and OS in EGFR mutants. The analysis showed that age, sex, smoking index, respiratory function, comorbidity index, and pathological stage did not significantly affect RFS and OS. However, performance status was found to be a significant factor affecting RFS, but not OS. Lymphatic invasion was also found to significantly affect OS.<br /><br />In conclusion, the study suggests that platinum-based adjuvant chemotherapy may not be as effective in EGFR mutant lung adenocarcinoma. The analysis of various factors in EGFR mutants showed that performance status and lymphatic invasion can influence RFS and OS, respectively. These findings highlight the importance of considering individual patient characteristics in determining the most appropriate treatment approach for EGFR mutant lung adenocarcinoma.

Asset Subtitle

Ken Onodera

Meta Tag

Speaker Ken Onodera

Topic Early Stage Non-small Cell Lung Cancer - Biomarkers

Keywords

platinum-based adjuvant chemotherapy

EGFR mutant lung adenocarcinoma

stage II-IIIA

overall survival

relapse-free survival

performance status

smoking index

respiratory function

comorbidity index

pathological stage